Search results
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
The Woonsocket Call· 2 days agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 3 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction ...
AbbVie (NYSE:ABBV) Stock Rating Reaffirmed by Cantor Fitzgerald
ETF DAILY NEWS· 6 hours agoAbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. Cantor Fitzgerald’s price ...
Pensionfund Sabic Sells 3,100 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 2 days agoPensionfund Sabic lowered its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 15.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 2 days agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis& ...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Garde Capital Inc.
ETF DAILY NEWS· 7 days agoGarde Capital Inc. lowered its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 60.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm ...
AbbVie (NYSE:ABBV) Shares Up 0%
ETF DAILY NEWS· 7 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0% during mid-day trading on Thursday . The company traded as high as $166.45 and last traded at $166.15. ABBV has been the topic ...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Capital Market Strategies LLC
ETF DAILY NEWS· 2 days agoCapital Market Strategies LLC cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 4.8% during the 1st quarter, HoldingsChannel reports. The fund owned 10,376 shares of the company’s stock ...
AbbVie Inc. (NYSE:ABBV) Holdings Cut by Carolina Wealth Advisors LLC
ETF DAILY NEWS· 2 days agoCarolina Wealth Advisors LLC decreased its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.2% during the 1st quarter, according to its most recent filing with the Securities ...